Supporter Spotlight

Metastatic Breast Cancer

At the Seventh Annual Women in Government Healthcare Summit in November 2016, a panel of speakers shared recommended action items for legislators to increase support for those living with metastatic breast cancer (MBC), the most advanced stage of breast cancer for which there is currently no cure. In collaboration with Pfizer, WIG presented experts Leslie Koby and MBC patient Beth Fairchild to share their stories with women state legislators from around the country.

Ms. Fairchild is involved in Breast Cancer: A Story Half Told, an initiative by Pfizer in partnership with advocates, patients and healthcare professionals that aims to elevate public understanding of MBC, dispel misperceptions, combat stigma and expand the breast cancer conversation to be more inclusive of this devastating disease.

During her presentation, Beth narrated her journey living with MBC and called on legislators to encourage and enable more research for this disease. She also called on governments to increase collaboration with patients and advocacy groups, as well as ensure that patients have access to innovative treatment and support.

Ms. Koby’s presentation echoed Beth’s, as she called for increased support for those living with MBC in the legislators’ states. She suggested introducing a resolution or memorial to increase awareness of the need for more research and access to appropriate care, as well as conducting an informational hearing in partnership with an advocacy group to get their feedback on local patients’ unmet needs.

Further, Leslie offered examples of current government programs that legislators could use to increase assistance for MBC patients in their communities. She described the importance of the Breast and Cervical Cancer Screening and Treatment Programs as critical tools to secure timely access to care for uninsured and underinsured women.

As a Women In Government supporter, Pfizer is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer.

For more information on Breast Cancer: A Story Half Told, please visit  For speaker presentations from the 2016 Healthcare Summit, please visit our Seventh Annual Healthcare Summit event page.

Ferring Pharmaceuticals

Ferring Pharmaceuticals, Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international company headquartered in Saint-Prex, Switzerland. Ferring identifies, develops and markets innovative products in therapeutic areas including women’s health, endocrinology, orthopedics, urology and infertility.

In its current work with Women in Government, Ferring is focusing on the growing issue of infertility. Infertility is a disease of the reproductive system that affects men and women equally and is recognized as such by the medical community, including the World Health Organization (WHO) and the American Congress of Obstetricians and Gynecologists (ACOG).

Infertility affects 1 in 8 couples in the United States, but with 21st century medical treatments, couples having trouble starting families have hope.  Indeed, modern medicine provides the means for promoting family building and helping those facing the disease of infertility to overcome it.

As of January, 2016, fifteen states offer some form of benefits for fertility coverage required by statute. Many of these statutes, however, require coverage for older, sub-optimal treatments.  The fact is, in the years since these states passed requirements for insurers to cover basic fertility treatments, more effective 21st century medical treatments have been advanced and developed. As a result of these new, advanced treatments, a much larger number of families are able to experience the joy of parenthood.

These same advances have sharply reduced the number of pregnancies resulting in multiple births (twins, triplets or more), which carry associated risk such as a higher incidence of mortality and premature delivery.  Reducing multiple births lowers these risks and significantly lowers costs. Indeed, according to a recent study, the national savings from fewer multiple births would be over $6 billion a year.

To learn more about Ferring, please visit​